All In Biotech

Drug Trial Radar · NCT07494435

Phase 2 Study of WGI-0301 Plus Nivolumab in Patients With HCC and RCC

An Open-Label Phase 2 Study of WGI-0301 Plus Nivolumab in Patients With Advanced Hepatocellular Carcinoma or Advance Renal Cell Carcinoma

Last checked: Nov 19, 2026Latest source record: Mar 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 230 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

230

Planned (sponsor's estimate)

Start

Jun 1, 2026

Primary completion

Jun 1, 2028

Study completion Sep 1, 2028

Sponsor

Sponsor type
Industry
First posted
Mar 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase II study being done at several hospitals without using a placebo. It will look at how safe and tolerable the drug WGI-0301 is when given together with nivolumab, how the body processes and responds to WGI-0301, and whether this combination shows early signs of working in people with advanced liver cancer or advanced kidney cancer.

Conditions

  • Hepato Cellular Carcinoma (HCC)
  • Renal Cell Cancer

Interventions

  • WGI-0301Drug

    WGI-0301 at Maximum Tolerated Dose (MTD)

  • Nivolumab (240 mg)Drug

    Nivolumab is given as an intravenous infusion, every 2 weeks

  • WGI-0301Drug

    WGI-0301 at dose level below Maximum Tolerated Dose (MTD-1)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy of WGI-0301 in Combination with NivolumabTime frame: 24 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • China Pharmaceutical University, Shanghai Gobroad Cancer Hospital

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.